In February, Moderna released its fourth-quarter numbers for the last three months of 2024. They weren't great. Sales totaling $966 million were just a fraction of the $2.8 billion it posted in the ...

CureVac and GSK have been racing behind Moderna to try to get the first mRNA flu vaccine to market. But, now, the European partners have come up against the exact same problem as their U.S. competitor ...

Moderna had a hoard of $19.3 billion in cash as the Covid-19 vaccine market peaked in early 2022 . That cash pile has been getting smaller ever since. The biotech lost $3.6 billion in 2024, and ...

Moderna is working to build a seasonal vaccines portfolio to spur growth. The FDA this week said it won’t review the biotech’s flu vaccine candidate. But, as demand for coronavirus vaccines waned ...